Found 161 articles for: "ustekinumab"
Tumor Necrosis Factor Inhibitor-Induced Psoriasis in a Pediatric Crohn’s Disease Patient Successfully Treated with Ustekinumab
March 2020 | Volume 19 | Issue 3 | Case Reports | 328 | Copyright © March 2020
Background: Tumor necrosis factor (TNF) inhibitors are widely used in pediatric patients with inflammatory bowel disease, as well as psoriasis. However, there is growing evidence that...
Read MoreEfficacy and Safety of Systemic Treatments for Skin and Joint Manifestations in Patients With Psoriasis
March 2020 | Volume 19 | Issue 3 | Original Article | 306 | Copyright © March 2020
Psoriasis is a chronic, systemic disease with features suggestive of autoimmune dysregulation. Patients with psoriasis vulgaris frequently experience systemic comorbidities, including cardiovascular a...
Read MoreReal World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
March 2020 | Volume 19 | Issue 3 | Case Reports | 316 | Copyright © March 2020
Psoriasis is a chronic, systemic, inflammatory skin disease with a risk of comorbidities and a potential high impact on patients’ quality of life....
Read MoreReal-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab
February 2020 | Volume 19 | Issue 2 | Original Article | 132 | Copyright © February 2020
Psoriasis is a chronic, inflammatory, remitting/relapsing autoimmune dermatologic condition that manifests with scaly, erythematous plaques. It has a significantly negative effect on patient quality o...
Read MoreManagement of Residual Psoriasis in Patients on Biologic Treatment
February 2020 | Volume 19 | Issue 2 | Original Article | 188 | Copyright © February 2020
While biologics are highly effective, most psoriasis patients do not achieve...
Read MoreClinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis
February 2020 | Volume 19 | Issue 2 | Original Article | 138 | Copyright © February 2020
The interleukin-17 (IL-17) pathway plays a crucial role in the development of psoriasis. Briefly, naive T cells differentiate into helper ...
Read MoreRapid and Sustained Improvement in a Patient With Plaque Psoriasis Switched to Brodalumab After Failing Treatment Clearance on Six Other Biologic Therapies
January 2020 | Volume 19 | Issue 1 | Case Reports | 86 | Copyright © January 2020
Psoriasis is a chronic, inflammatory, remitting/relapsing autoimmune condition involving a dysregulated inflammatory response of the interleukin (IL) 23/T-helper (Th)-17 pathway. Greater understanding...
Read MoreNon-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
October 2019 | Volume 18 | Issue 10 | Editorials | 1059 | Copyright © October 2019
Patients with psoriasis are at increased risk of developing non melanoma skin cancer (NMSC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).1,2 The risk is especiall...
Read MoreTreatment of Recalcitrant Acrodermatitis Continua of Hallopeau With Brodalumab
October 2019 | Volume 18 | Issue 10 | Editorials | 1047 | Copyright © October 2019
Acrodermatitis continua of Hallopeau (ACH) is a relatively rare chronic disorder with clinical findings of pustules and erythematous plaques on the digits.1 Although it is a variant of pustular psoria...
Read MoreThe Paradoxical Induction of Crohn’s Disease Following Treatment of Psoriatic Arthritis With Etanercept
August 2019 | Volume 18 | Issue 8 | Case Reports | 832 | Copyright © August 2019
Introduction: While psoriasis, psoriatic arthritis, and Crohn’s Disease (CD) all share a common central pathogenesis pathway and a wide overlap of treatment regime, discrepancie...
Read MoreA Review of Topical Corticosteroid Foams
August 2019 | Volume 18 | Issue 8 | Original Article | 756 | Copyright © August 2019
Background: Topical corticosteroids are efficacious treatment options for multiple dermatoses. However, ointments and cream corticosteroid vehicles can be cumbersome to patients and m...
Read MorePrescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database
August 2019 | Volume 18 | Issue 8 | Original Article | 745 | Copyright © August 2019
Introduction: Selecting a systemic therapy for patients with psoriasis is a complex process, based on a variety of factors including psoriasis severity, comorbid health conditions, ac...
Read MoreCombination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry
August 2019 | Volume 18 | Issue 8 | Original Article | 731 | Copyright © August 2019
Importance: There are increasing options for systemic combination therapy for psoriasis but a lack of literature around the characteristics of patients who are started on these regime...
Read MoreARTICLE: IL-23 Versus IL-17 in the Pathogenesis of Psoriasis: There Is More to the Story Than IL-17A
August 2019 | Volume 18 | Issue 8 | Supplement Individual Articles | 202 | Copyright © August 2019
Our understanding of psoriasis pathogenesis has evolved considerably. Cytokines within the TH1 and TH17 pathways have been found to be critical in psoriasis immunopathology. The TH17 pathway, which is...
Read MoreSuccessful Treatment of Refractory Plaque-Type Psoriasis and Psoriatic Arthritis With Guselkumab and Adalimumab Combination Therapy: A Case Report
April 2019 | Volume 18 | Issue 4 | Case Reports | 394 | Copyright © April 2019
COPY: A number of biologics have been approved for use in plaque-type psoriasis. They act by either blocking the action of a specific type of cell or protein in the immune system.
CASE P...
Read MoreGrover’s Disease Treated With Total Skin Electron Beam Radiotherapy
April 2019 | Volume 18 | Issue 4 | Case Reports | 392 | Copyright © April 2019
Persistent Grover's disease can cause significant symptoms of pruritus thereby decreasing quality of life. Many patients undergo successful conservative management of their disease; however, a subset...
Read MoreTreatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review
April 2019 | Volume 18 | Issue 4 | Original Article | 387 | Copyright © April 2019
INTRODUCTION: Biologics have transformed the management of moderate-to-severe psoriasis. The risk of developing a malignancy during treatment is an important consideration, and many studies have b...
Read MoreOnset of Action of Antipsoriatic Drugs for Moderate-to-Severe Plaque Psoriasis: An Update
March 2019 | Volume 18 | Issue 3 | Original Article | 229 | Copyright © March 2019
Objectives: The time that drugs for moderate-to-severe psoriasis take to see a clinically meaningful improvement (TOA) is one of the most important attributes of treatment success. This study synth...
Read MoreSystemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in Practice
February 2019 | Volume 18 | Issue 2 | Original Article | 122 | Copyright © February 2019
Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects around 13% of children and 7% of adults in the US. It can have a significant impact on the quality of life (QoL) of affected ...
Read MoreNavigating Targeted Therapeutics in Dermatology: Biologics and Small Molecules
December 2018 | Volume 17 | Issue 12 | Features | 1330 | Copyright © December 2018
Dermatology is entering an exciting era with new, targeted immune-modulating medications for treating a variety of dermatologic conditions including psoriasis, atopic dermatitis (AD), and hidradenitis...
Read More